Literature DB >> 22189617

Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients.

Futao Hou1, Weijie Yuan, Jin Huang, Liyuan Qian, Zhikang Chen, Jie Ge, Shaobin Wu, Jinxiang Chen, Jixu Wang, Zihua Chen.   

Abstract

The expression of EphA2 and three epithelial-mesenchymal transition-related proteins (E-cadherin, β-catenin and vimentin) was detected by immunohistochemistry in human gastric cancer and normal gastric mucosa. The expression of EphA2 and vimentin was significantly higher in gastric cancer tissues than in normal gastric mucosa tissues, and similar results were found for negative E-cadherin expression and ectopic β-catenin expression. Further analysis showed that the expression of EphA2 was closely correlated with the depth of tumor invasion, tumor-node-metastasis (TNM) stages and lymph node metastasis. Down-regulated expression of the epithelial protein E-cadherin, overexpression of the mesenchymal protein vimentin and ectopic expression of β-catenin were associated with the depth of tumor invasion, tumor differentiation, TNM stages and lymph node metastasis. The Spearman rank test indicated that the positive expression of EphA2 was negatively associated with E-cadherin expression and was positively correlated with β-catenin ectopic expression and vimentin expression. In addition, the Kaplan-Meier survival analysis showed that the overexpression of EphA2 and vimentin, ectopic expression of β-catenin and down-regulation of E-cadherin indicate a poor outcome. Moreover, multivariate Cox analysis showed that TNM stages, lymph node metastasis, EphA2 expression, E-cadherin expression and β-catenin ectopic expression were independent prognostic factors for postoperative gastric cancer. These findings indicate that the overexpression of EphA2 correlates with the loss of epithelial proteins and the appearance of mesenchymal proteins. Therefore, EphA2 may play a role in epithelial-mesenchymal transition in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189617     DOI: 10.1007/s12032-011-0127-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  47 in total

1.  E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes.

Authors:  P R Almeida; V A Ferreira; C C Santos; F D Rocha-Filho; R R Feitosa; E A A Falcão; B K Cavada; R A Ribeiro
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

Review 2.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

3.  Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms.

Authors:  Hui-Ping Hsu; Yan-Shen Shan; Ying-Tai Jin; Ming-Derg Lai; Pin-Wen Lin
Journal:  J Surg Oncol       Date:  2010-04-01       Impact factor: 3.454

Review 4.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.

Authors:  Reneé C Ireton; Jin Chen
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

5.  AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell-cell adhesion.

Authors:  Jacqueline M Benjamin; Adam V Kwiatkowski; Changsong Yang; Farida Korobova; Sabine Pokutta; Tatyana Svitkina; William I Weis; W James Nelson
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

6.  Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.

Authors:  Weijie Yuan; Zhikang Chen; Shaobin Wu; Jie Ge; Shi Chang; Xianwei Wang; Jingxiang Chen; Zihua Chen
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

Authors:  Aparna A Kamat; Donna Coffey; William M Merritt; Elizabeth Nugent; Diana Urbauer; Yvonne G Lin; Creighton Edwards; Russell Broaddus; Robert L Coleman; Anil K Sood
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

8.  Transactivation of vimentin by beta-catenin in human breast cancer cells.

Authors:  Christine Gilles; Myriam Polette; Mélanie Mestdagt; Béatrice Nawrocki-Raby; Philippe Ruggeri; Philippe Birembaut; Jean-Michel Foidart
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Dan Cui; Mi-Jin Lee; Goung-Ran Yu; In-Hee Kim; Hee-Chul Yu; Eun-Young Song; Dae-Ghon Kim
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

10.  Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Ludmila Prudkin; Diane D Liu; Natalie C Ozburn; Menghong Sun; Carmen Behrens; Ximing Tang; Kathlynn C Brown; B Nebiyou Bekele; Cesar Moran; Ignacio I Wistuba
Journal:  Mod Pathol       Date:  2009-03-06       Impact factor: 7.842

View more
  22 in total

1.  MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Authors:  Ruixin Li; Weijie Yuan; Wenjuan Mei; Keda Yang; Zihua Chen
Journal:  Mol Cell Biochem       Date:  2014-07-26       Impact factor: 3.396

2.  Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.

Authors:  Xiaolin Wang; Haifei Xu; Zhijun Wu; Xiao Chen; Jiandong Wang
Journal:  Int J Exp Pathol       Date:  2017-04-19       Impact factor: 1.925

Review 3.  Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis.

Authors:  Li-Fu Li; Zheng-Jie Wei; Hong Sun; Bo Jiang
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner.

Authors:  Hea Nam Hong; You Jin Won; Ju Hee Shim; Hyun Ji Kim; Seung Hee Han; Byung Sik Kim; Hee Sung Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-12       Impact factor: 4.553

5.  MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.

Authors:  Hesheng Li; Qinglei Sun; Bing Han; Xingquan Yu; Baoguang Hu; Sanyuan Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma.

Authors:  Anchalee Techasen; Nisana Namwat; Watcharin Loilome; Pornpan Bungkanjana; Narong Khuntikeo; Anucha Puapairoj; Patcharee Jearanaikoon; Hideyuki Saya; Puangrat Yongvanit
Journal:  Med Oncol       Date:  2012-08-19       Impact factor: 3.064

Review 7.  Contactin 1: A potential therapeutic target and biomarker in gastric cancer.

Authors:  De-Hu Chen; Ji-Wei Yu; Bo-Jian Jiang
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

Review 8.  Epithelial-mesenchymal transition in gastric cancer.

Authors:  Lei Huang; Ruo-Lin Wu; A-Man Xu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

9.  EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.

Authors:  Linfeng Mao; Weijie Yuan; Kaimei Cai; Chen Lai; Changhao Huang; Yi Xu; Shangwei Zhong; Chen Yang; Ran Wang; Pengwei Zeng; Heyuan Huang; Zhikang Chen; Zihua Chen
Journal:  Oncogene       Date:  2021-05-03       Impact factor: 9.867

10.  High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome.

Authors:  Jinsheng Xu; Junxia Zhang; Liwen Cui; Huiran Zhang; Shenglei Zhang; Yaling Bai
Journal:  Oncol Lett       Date:  2014-05-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.